symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BMEA,11.43,-1.055025,471726,404634573,0,6.04-43.69,0.72,"Biomea Fusion, Inc.",USD,0001840439,US09077A1060,09077A106,NASDAQ Global Select,NASDAQ,Biotechnology,https://biomeafusion.com,"Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.",Mr. Thomas Andrew Butler,Healthcare,US,86,650 980 9099,900 Middlefield Road,Redwood City,CA,94063,,0,https://financialmodelingprep.com/image-stock/BMEA.png,2021-04-16,False,False,True,False,False
